Received Aug 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 342DD | — |
Vaccine extra dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 12-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number 342DD, expiry date 30-APR-2026) for prophylaxis. Previously administered products included Menveo (received 1st dose in June 2024). On 30-JUN-2025, the patient received the 2nd dose of Menveo. On 30-JUN-2025, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: Vaccine extra dose). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 30-AUG-2025 The nurse reported that the patient received two doses of Menveo one year apart, at age 11 and age 12, which led to extra dose administered. First dose was administered back in June 2024 and last one on 30 June 2025. The reporter was ask there any harm since it was not spaced correctly. The vaccine administration facility was the same as primary reporter.